A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)
This study is currently recruiting participants.
Verified April 2013 by UCB, Inc.
Sponsor:
UCB Pharma SA
Information provided by (Responsible Party):
UCB, Inc. ( UCB Pharma SA )
ClinicalTrials.gov Identifier:
NCT01519791
First received: January 19, 2012
Last updated: April 29, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active Rheumatoid Arthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Biological: Certolizumab Pegol + Methotrexate (MTX) Biological: Placebo + Methotrexate (MTX) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis |
Resource links provided by NLM:
Further study details as provided by UCB, Inc.:
Primary Outcome Measures:
- Percentage of subjects in sustained remission at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Sustained remission is defined as a Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28[ESR]) < 2.6 at both Weeks 40 and 52.
Secondary Outcome Measures:
- Percentage of subjects in sustained Low Disease Activity (LDA) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Sustained LDA is defined as a Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28[ESR]) ≤ 3.2 at both Weeks 40 and 52.
- Change from Baseline in modified Total Sharp Score (mTSS) to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]Van der Heijde modified Total Sharp Score (mTSS).
- Percentage of subjects with radiographic non-progression from Baseline to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]Radiographic non-progression is defined as change in mTSS ≤ 0.5.
- Change from Baseline in the joint erosion score to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
- Change from Baseline in the joint narrowing score to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
- Percentage of subjects meeting the American College of Rheumatology 20% response criteria (ACR20) at Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Percentage of subjects meeting the American College of Rheumatology 50% response criteria (ACR50) at Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Percentage of subjects meeting the American College of Rheumatology 70% response criteria (ACR70) at Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Percentage of subjects meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) remission criteria at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
The ACR/EULAR 2011 remission criteria is defined as:
Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1, C-reactive protein (CRP) ≤ 1 mg/dl and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.
- Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
- Percentage of subjects with Simplified Disease Activity Index (SDAI) ≤ 3.3 at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
- Percentage of subjects with Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) < 2.6 at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
- Percentage of subjects meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) remission criteria simplified for clinical practice at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:
Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.
- Percentage of subjects achieving a good or moderate European League Against Rheumatism (EULAR) response at Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
Good response is defined as:
DAS28[ESR] ≤ 3.2 and decrease from Baseline by > 1.2;
moderate response is defined as achievement of one of the following:
- DAS28[ESR] ≤ 3.2 and decrease from Baseline > 0.6 and ≤ 1.2
- DAS28[ESR] > 3.2 and ≤ 5.1 and decrease from Baseline > 0.6
- DAS28[ESR] > 5.1 and decrease from Baseline >1.2.
- Change from Baseline in Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
- Change from Baseline in Clinical Disease Activity Index (CDAI) to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
- Change from Baseline in Simplified Disease Activity Index (SDAI) to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
- Percentage of subjects with a Health Assessment Questionnaire- Disability Index (HAQ-DI) ≤ 0.5 at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.
The total score ranges from 0 to 3 with lower scores meaning lower disability.
- Change from Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]
The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.
The total score ranges from 0 to 3 with lower scores meaning lower disability.
- Change from Baseline in the Bristol Rheumatoid Arthritis Fatigue- Multidimensional Questionnaire (BRAF-MDQ) total score to Week 52 [ Time Frame: From Baseline (Week 0) to Week 52 ] [ Designated as safety issue: No ]BRAF-MDQ total score ranges from 0 to 70 (with higher scores indicating worse fatigue).
- Number of work days missed (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of work days missed in the last month.
- Number of work days with reduced productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of work days with reduced productivity in the last month.
- Interference with work productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).
- Number of days with no household work (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of days with no household work in the last month.
- Number of days with reduced household work productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of days with reduced household work productivity in the last month.
- Number of days with hired outside help (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of days with hired outside help in the last month.
- Number of days missed of family/social/leisure activities (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]Number of days missed of family/social/leisure activities in the last month.
- Interference with household work productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).
- Percentage of subjects achieving Low Disease Activity (LDA) at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]LDA is defined as achieving a Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) ≤ 3.2.
| Estimated Enrollment: | 800 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Certolizumab Pegol + Methotrexate |
Biological: Certolizumab Pegol + Methotrexate (MTX)
Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50. The MTX treatment is to be initiated at a dose of 10 mg per Week. The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Other Names:
|
| Placebo Comparator: Placebo + Methotrexate |
Biological: Placebo + Methotrexate (MTX)
2 syringes Placebo at Baseline, Week 2 and Week 4 + MTX, followed by 1 syringe Placebo every 2 Weeks + MTX. The MTX treatment is to be initiated at a dose of 10 mg per Week. The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Other Name: MTX
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects must have a time since diagnosis of adult-onset Rheumatoid Arthritis (RA) less than 1 year as defined by the 2010 ACR/EULAR classification criteria from Screening Visit
- Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide Antibody (anti-CCP)
- Active RA disease
- DMARD-naïve
- Subject is naïve to RA related biologics
Exclusion Criteria:
- A diagnosis of any other inflammatory Arthritis
- History of infected joint prosthesis, or other significant infection and other serious medical condition
- Known Tuberculosis (TB) disease or high risk of acquiring TB infection
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01519791
Hide Study Locations
Contacts
| Contact: UCB Clinical Trial Call Center | +1 877 822 9493 |
Hide Study LocationsLocations
| United States, Alabama | |
| 209 | Recruiting |
| Birmingham, Alabama, United States | |
| 170 | Recruiting |
| Huntsville, Alabama, United States | |
| 180 | Recruiting |
| Mobile, Alabama, United States | |
| United States, Arizona | |
| 247 | Recruiting |
| Glendale, Arizona, United States | |
| 165 | Recruiting |
| Paradise Valley, Arizona, United States | |
| 234 | Recruiting |
| Paradise Valley, Arizona, United States | |
| 187 | Recruiting |
| Phoenix, Arizona, United States | |
| 243 | Recruiting |
| Phoenix, Arizona, United States | |
| 251 | Recruiting |
| Tucson, Arizona, United States | |
| United States, Arkansas | |
| 156 | Withdrawn |
| Little Rock, Arkansas, United States | |
| United States, California | |
| 160 | Recruiting |
| Covina, California, United States | |
| 257 | Recruiting |
| Hemet, California, United States | |
| 164 | Withdrawn |
| Huntington Beach, California, United States | |
| 159 | Recruiting |
| Los Angeles, California, United States | |
| 201 | Recruiting |
| San Leandro, California, United States | |
| 202 | Recruiting |
| Upland, California, United States | |
| 172 | Recruiting |
| Whittier, California, United States | |
| United States, Florida | |
| 190 | Recruiting |
| Fort Lauderdale, Florida, United States | |
| 173 | Withdrawn |
| Jacksonville, Florida, United States | |
| 196 | Recruiting |
| Jupiter, Florida, United States | |
| 238 | Recruiting |
| Lake Mary, Florida, United States | |
| 232 | Recruiting |
| Miami, Florida, United States | |
| 213 | Recruiting |
| Naples, Florida, United States | |
| 214 | Recruiting |
| Ocala, Florida, United States | |
| 237 | Recruiting |
| Orange Park, Florida, United States | |
| 255 | Recruiting |
| Orlando, Florida, United States | |
| 163 | Recruiting |
| Palm Harbor, Florida, United States | |
| 166 | Recruiting |
| Plantation, Florida, United States | |
| 192 | Recruiting |
| Sarasota, Florida, United States | |
| 200 | Recruiting |
| Vero Beach, Florida, United States | |
| United States, Idaho | |
| 226 | Recruiting |
| Coeur D'alene, Idaho, United States | |
| United States, Illinois | |
| 219 | Recruiting |
| Rock Island, Illinois, United States | |
| 244 | Recruiting |
| Springfield, Illinois, United States | |
| United States, Indiana | |
| 224 | Recruiting |
| South Bend, Indiana, United States | |
| 222 | Withdrawn |
| Terre Haute, Indiana, United States | |
| United States, Iowa | |
| 215 | Recruiting |
| Cedar Rapids, Iowa, United States | |
| United States, Kansas | |
| 191 | Recruiting |
| Wichita, Kansas, United States | |
| 210 | Recruiting |
| Wichita, Kansas, United States | |
| United States, Maryland | |
| 218 | Recruiting |
| Baltimore, Maryland, United States | |
| 177 | Recruiting |
| Hagerstown, Maryland, United States | |
| United States, Michigan | |
| 199 | Recruiting |
| Kalamazoo, Michigan, United States | |
| United States, Minnesota | |
| 198 | Recruiting |
| Eagan, Minnesota, United States | |
| 253 | Recruiting |
| Rochester, Minnesota, United States | |
| United States, Mississippi | |
| 203 | Recruiting |
| Tupelo, Mississippi, United States | |
| United States, Missouri | |
| 179 | Recruiting |
| St. Louis, Missouri, United States | |
| United States, Nebraska | |
| 181 | Recruiting |
| Lincoln, Nebraska, United States | |
| United States, Nevada | |
| 256 | Recruiting |
| Reno, Nevada, United States | |
| United States, New Hampshire | |
| 229 | Recruiting |
| Lebanon, New Hampshire, United States | |
| United States, New Jersey | |
| 228 | Recruiting |
| Clifton, New Jersey, United States | |
| United States, New Mexico | |
| 207 | Recruiting |
| Albuquerque, New Mexico, United States | |
| United States, New York | |
| 176 | Recruiting |
| Brooklyn, New York, United States | |
| 242 | Recruiting |
| Plainview, New York, United States | |
| 227 | Recruiting |
| Rochester, New York, United States | |
| United States, North Carolina | |
| 236 | Recruiting |
| Durham, North Carolina, United States | |
| 246 | Withdrawn |
| Rocky Mount, North Carolina, United States | |
| United States, North Dakota | |
| 182 | Withdrawn |
| Minot, North Dakota, United States | |
| United States, Ohio | |
| 231 | Recruiting |
| Cleveland, Ohio, United States | |
| 245 | Recruiting |
| Middleburg Heights, Ohio, United States | |
| United States, Oklahoma | |
| 241 | Recruiting |
| Oklahoma City, Oklahoma, United States | |
| United States, Oregon | |
| 186 | Recruiting |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| 195 | Recruiting |
| Bethlehem, Pennsylvania, United States | |
| 167 | Recruiting |
| Duncansville, Pennsylvania, United States | |
| 220 | Withdrawn |
| Willow Grove, Pennsylvania, United States | |
| 168 | Recruiting |
| Wyomissing, Pennsylvania, United States | |
| United States, South Carolina | |
| 205 | Recruiting |
| Columbia, South Carolina, United States | |
| 189 | Recruiting |
| North Charleston, South Carolina, United States | |
| United States, Tennessee | |
| 204 | Recruiting |
| Hendersonville, Tennessee, United States | |
| 248 | Withdrawn |
| Memphis, Tennessee, United States | |
| United States, Texas | |
| 217 | Recruiting |
| Allen, Texas, United States | |
| 185 | Recruiting |
| Amarillo, Texas, United States | |
| 161 | Recruiting |
| Austin, Texas, United States | |
| 178 | Recruiting |
| Corpus Christi, Texas, United States | |
| 162 | Recruiting |
| Dallas, Texas, United States | |
| 206 | Recruiting |
| Houston, Texas, United States | |
| 184 | Recruiting |
| Houston, Texas, United States | |
| 158 | Recruiting |
| Mesquite, Texas, United States | |
| 175 | Recruiting |
| Nassau Bay, Texas, United States | |
| 249 | Recruiting |
| Plano, Texas, United States | |
| 197 | Recruiting |
| San Antonio, Texas, United States | |
| 223 | Recruiting |
| Sugar Land, Texas, United States | |
| United States, Washington | |
| 233 | Recruiting |
| Kennewick, Washington, United States | |
| 221 | Withdrawn |
| Seattle, Washington, United States | |
| United States, West Virginia | |
| 183 | Recruiting |
| Clarksburg, West Virginia, United States | |
| United States, Wisconsin | |
| 174 | Recruiting |
| Glendale, Wisconsin, United States | |
| Argentina | |
| 276 | Recruiting |
| Buenos Aires, Argentina | |
| 279 | Recruiting |
| San Juan, Argentina | |
| 291 | Recruiting |
| Tucuman, Argentina | |
| Australia, New South Wales | |
| 6 | Recruiting |
| Coffs Harbour, New South Wales, Australia | |
| Australia, Queensland | |
| 2 | Recruiting |
| Herson, Queensland, Australia | |
| 1 | Recruiting |
| Maroochydore, Queensland, Australia | |
| Australia, South Australia | |
| 8 | Recruiting |
| Woodville South, South Australia, Australia | |
| Australia, Victoria | |
| 5 | Recruiting |
| Fitzroy, Victoria, Australia | |
| 4 | Recruiting |
| Geelong, Victoria, Australia | |
| 3 | Recruiting |
| Malvern, Victoria, Australia | |
| Australia, Western Australia | |
| 7 | Recruiting |
| Perth, Western Australia, Australia | |
| Austria | |
| 50 | Recruiting |
| Wien, Austria | |
| Belgium | |
| 51 | Recruiting |
| Brussels, Belgium | |
| 31 | Recruiting |
| Gent, Belgium | |
| 126 | Recruiting |
| Gilly, Belgium | |
| 36 | Recruiting |
| Kortrijk, Belgium | |
| 30 | Recruiting |
| Leuven, Belgium | |
| 65 | Recruiting |
| Yvoir, Belgium | |
| Canada, British Columbia | |
| 240 | Recruiting |
| Kelowna, British Columbia, Canada | |
| Canada, Ontario | |
| 235 | Recruiting |
| Hamilton, Ontario, Canada | |
| Canada, Quebec | |
| 188 | Recruiting |
| Montreal, Quebec, Canada | |
| 194 | Recruiting |
| Trois-rivieres, Quebec, Canada | |
| Colombia | |
| 303 | Recruiting |
| Barranquilla, Colombia | |
| 293 | Recruiting |
| Bogota, Colombia | |
| 299 | Recruiting |
| Bogota, Colombia | |
| 272 | Recruiting |
| Bogota, Colombia | |
| 297 | Recruiting |
| Bucaramanga, Colombia | |
| 288 | Recruiting |
| Chia, Colombia | |
| 298 | Recruiting |
| Medellin, Colombia | |
| 271 | Recruiting |
| Medellin, Colombia | |
| Czech Republic | |
| 108 | Recruiting |
| Brno, Czech Republic | |
| 124 | Recruiting |
| Bruntal, Czech Republic | |
| 38 | Recruiting |
| Hradec Kralove, Czech Republic | |
| 37 | Recruiting |
| Praha, Czech Republic | |
| France | |
| 95 | Recruiting |
| Clermont Ferrand, France | |
| 16 | Recruiting |
| Le Kremlin Bicetre, France | |
| 85 | Recruiting |
| Le Mans, France | |
| 48 | Recruiting |
| Marseille, France | |
| 88 | Recruiting |
| Montpellier Cedex 5, France | |
| 34 | Recruiting |
| Orleans, France | |
| 79 | Recruiting |
| Strasbourg, France | |
| Germany | |
| 52 | Recruiting |
| Bad Doberan, Germany | |
| 17 | Recruiting |
| Bayreuth, Germany | |
| 113 | Recruiting |
| Berlin, Germany | |
| 120 | Recruiting |
| Berlin, Germany | |
| 89 | Recruiting |
| Erfurt, Germany | |
| 70 | Recruiting |
| Frankfurt, Germany | |
| 28 | Withdrawn |
| Goslar, Germany | |
| 71 | Recruiting |
| Hamburg, Germany | |
| 81 | Recruiting |
| Hildesheim, Germany | |
| 127 | Recruiting |
| Lingen, Germany | |
| 61 | Recruiting |
| München, Germany | |
| 53 | Recruiting |
| Planegg, Germany | |
| 132 | Recruiting |
| Ratingen, Germany | |
| 49 | Recruiting |
| Rendsburg, Germany | |
| 69 | Recruiting |
| Rheine, Germany | |
| 114 | Recruiting |
| Würzburg, Germany | |
| 59 | Recruiting |
| Zerbst, Germany | |
| Hungary | |
| 18 | Recruiting |
| Budapest, Hungary | |
| 21 | Recruiting |
| Budapest, Hungary | |
| 86 | Recruiting |
| Eger, Hungary | |
| 20 | Recruiting |
| Gyula, Hungary | |
| 112 | Recruiting |
| Heviz, Hungary | |
| 131 | Recruiting |
| Szolnok, Hungary | |
| 110 | Recruiting |
| Szombathely, Hungary | |
| 19 | Recruiting |
| Veszprem, Hungary | |
| Ireland | |
| 33 | Recruiting |
| Cork, Ireland | |
| 54 | Recruiting |
| Dublin, Ireland | |
| 104 | Recruiting |
| Dublin, Ireland | |
| 32 | Recruiting |
| Limerick, Ireland | |
| Italy | |
| 115 | Recruiting |
| Ferrara, Italy | |
| 122 | Recruiting |
| Milano, Italy | |
| 29 | Recruiting |
| Padova, Italy | |
| 91 | Withdrawn |
| Prato, Italy | |
| 40 | Recruiting |
| Reggio Emilia, Italy | |
| 72 | Recruiting |
| Roma, Italy | |
| 116 | Recruiting |
| Roma, Italy | |
| 41 | Recruiting |
| Valeggio, Italy | |
| Mexico | |
| 281 | Recruiting |
| Durango, Mexico | |
| 286 | Recruiting |
| Guadalajara, Mexico | |
| 302 | Recruiting |
| Merida, Mexico | |
| 292 | Recruiting |
| Mexico City, Mexico | |
| 280 | Recruiting |
| Monterrey, Mexico | |
| 294 | Recruiting |
| San Luis Potosi, Mexico | |
| Monaco | |
| 78 | Recruiting |
| Monaco, Monaco | |
| Netherlands | |
| 43 | Recruiting |
| Den Haag, Netherlands | |
| 66 | Recruiting |
| Den Haag, Netherlands | |
| 90 | Recruiting |
| Gouda, Netherlands | |
| 42 | Recruiting |
| Leiden, Netherlands | |
| Poland | |
| 128 | Recruiting |
| Bydgoszcz, Poland | |
| 67 | Recruiting |
| Elblag, Poland | |
| 46 | Recruiting |
| Katowice, Poland | |
| 99 | Recruiting |
| Krakow, Poland | |
| 92 | Recruiting |
| Poznan, Poland | |
| 74 | Recruiting |
| Torun, Poland | |
| 62 | Recruiting |
| Ustron, Poland | |
| 100 | Recruiting |
| Warszawa, Poland | |
| 44 | Recruiting |
| Wroclaw, Poland | |
| Romania | |
| 58 | Recruiting |
| Brasov, Romania | |
| 26 | Recruiting |
| Bucharest, Romania | |
| 111 | Recruiting |
| Bucharest, Romania | |
| 22 | Recruiting |
| Bucharest, Romania | |
| 25 | Recruiting |
| Bucharest, Romania | |
| 23 | Recruiting |
| Cluj-napoca, Romania | |
| 24 | Recruiting |
| Iasi, Romania | |
| 57 | Recruiting |
| Iasi, Romania | |
| Spain | |
| 93 | Recruiting |
| A Coruna, Spain | |
| 47 | Recruiting |
| Madrid, Spain | |
| 64 | Recruiting |
| Madrid, Spain | |
| 63 | Active, not recruiting |
| Santiago de Compostela, Spain | |
| 103 | Withdrawn |
| Sevilla, Spain | |
| Sweden | |
| 102 | Recruiting |
| Falun, Sweden | |
| 76 | Recruiting |
| Göteborg, Sweden | |
| 82 | Recruiting |
| Huddinge, Sweden | |
| 106 | Recruiting |
| Lund, Sweden | |
| 123 | Recruiting |
| Malmö, Sweden | |
| 77 | Recruiting |
| Stockholm, Sweden | |
| 75 | Recruiting |
| Uppsala, Sweden | |
| Switzerland | |
| 107 | Recruiting |
| Aarau, Switzerland | |
| 118 | Recruiting |
| Fribourg, Switzerland | |
| 87 | Recruiting |
| Lausanne, Switzerland | |
| 68 | Recruiting |
| St. Gallen, Switzerland | |
| United Kingdom | |
| 55 | Recruiting |
| Bury-st-edmunds, United Kingdom | |
| 125 | Recruiting |
| Cannock, United Kingdom | |
| 105 | Recruiting |
| Dudley, United Kingdom | |
| 56 | Recruiting |
| Leeds, United Kingdom | |
| 27 | Recruiting |
| London, United Kingdom | |
| 121 | Recruiting |
| London, United Kingdom | |
| 80 | Recruiting |
| Sheffield, United Kingdom | |
| 119 | Recruiting |
| York, United Kingdom | |
Sponsors and Collaborators
UCB Pharma SA
Investigators
| Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
More Information
No publications provided
| Responsible Party: | UCB, Inc. ( UCB Pharma SA ) |
| ClinicalTrials.gov Identifier: | NCT01519791 History of Changes |
| Other Study ID Numbers: | RA0055A, 2011-001729-25 |
| Study First Received: | January 19, 2012 |
| Last Updated: | April 29, 2013 |
| Health Authority: | United States: Food and Drug Administration Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica Australia: Department of Health and Ageing Therapeutic Goods Administration Austria: Federal Office for Safety in Health Care Belgium: Federal Agency for Medicinal Products and Health Products Canada: Health Canada Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos Czech Republic: State Institute for Drug Control France: L’Agence nationale de sécurité du médicament et des produits de santé Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy Ireland: Irish Medicines Board Italy: The Italian Medicines Agency Mexico: Ministry of Health Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Romania: National Medicines Agency Spain: Agencia Española de Medicamentos y Productos Sanitarios Sweden: Medical Products Agency Switzerland: Swissmedic Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by UCB, Inc.:
|
Certolizumab Pegol - Cimzia Methotrexate Rheumatoid Arthritis |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Antirheumatic Agents Methotrexate Immunoglobulin Fab Fragments Therapeutic Uses Pharmacologic Actions Abortifacient Agents, Nonsteroidal |
Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on May 22, 2013